BLTE
Belite Bio, Inc
NASDAQ · Healthcare · Biotechnology · US
$193.61
+13.16%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 58.8M | 45.4M | 29.9M | 24.8M | 8.9M |
| SG&A Expense | 59.9M | 38.8M | 10.1M | 6.8M | 4.0M |
| General & Admin Expense | 43.2M | 38.8M | 10.1M | 6.8M | 4.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 118.7M | 84.2M | 40.0M | 31.7M | 12.8M |
| Cost and Expenses | 118.7M | 84.2M | 40.0M | 31.7M | 12.8M |
| Operating Income (EBIT) | (118.7M) | (84.2M) | (40.0M) | (31.7M) | (12.8M) |
| Non-Operating | |||||
| Interest Income | — | — | 3.7M | 74.0K | 23.0K |
| Interest Expense | — | — | 20.0K | 25.0K | 16.0K |
| Net Interest Income | — | — | 3.7M | 49.0K | 7.0K |
| Other Non-Op Income/Expense | 16.4M | 6.6M | 3.9M | 45.0K | 173.0K |
| Non-Operating Income (excl Interest) | (4.5M) | (6.6M) | (3.9M) | (70.0K) | (189.0K) |
| EBT (Pre-Tax Income) | (102.3M) | (77.6M) | (36.1M) | (31.6M) | (12.6M) |
| Income Tax Expense | 55.0K | — | 6.0K | 9.0K | — |
| Bottom Line | |||||
| Net Income | (102.4M) | (77.6M) | (36.1M) | (31.6M) | (12.6M) |
| Earnings from Cont. Ops | (102.4M) | (77.6M) | (36.1M) | (31.6M) | (12.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (102.4M) | (77.6M) | (36.1M) | (31.6M) | (12.6M) |
| Per Share | |||||
| Basic EPS | ($2.76) | ($2.31) | ($1.18) | ($1.19) | ($0.63) |
| Diluted EPS | ($2.76) | ($2.31) | ($1.18) | ($1.19) | ($0.63) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 40.2M | 33.5M | 30.5M | 26.6M | 20.0M |
| Diluted Shares Outstanding | 40.2M | 33.5M | 30.5M | 26.6M | 20.0M |
| Profitability Metrics | |||||
| EBITDA | (114.2M) | (77.1M) | (35.7M) | (31.2M) | (12.4M) |
| D&A | 117.00 | 464.0K | 449.0K | 399.0K | 198.0K |
| EBIT | (114.2M) | (77.6M) | (36.1M) | (31.6M) | (12.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026